KISUNLA conc perf 350 mg 1 pce

7680695230017 CH-69523 N06DX05 01.99.0.

No images available

Details

Product number
6952301
CPT
-
Packaging group
1
Unit
Durchstechflasche(n)
Composition
donanemabum 350 mg, natrii citras dihydricus, acidum citricum, saccharum, polysorbatum 80, aqua ad iniectabile ad solutionem pro 20 ml corresp. natrium 11.5 mg.

Articles (1)

Kisunla 350 mg, Konzentrat zur Herstellung einer Infusionslösung
Konzentrat
1
View

Official Swissmedic V2 data

Additional information from the official database

Official medical documents

Patient information leaflet
Allemand
23/02/2026
Patient information leaflet
Français
23/02/2026
Patient information leaflet
Italien
23/02/2026
Professional SmPC
Allemand
23/02/2026
Professional SmPC
Français
23/02/2026
Professional SmPC
Italien
23/02/2026

Detailed composition

Substance Quantity Type Category
donanemabum
350.0 MG Substance Wirkstoff (Principe actif)
natrii citras dihydricus
- Substance HNIDK
acidum citricum
- Substance HNIDK
saccharum
- Substance HNIDK
polysorbatum 80
- Substance HNIDK
aqua ad iniectabile
- Substance HNIDK
natrium
11.5 MG Substance HBESI

Authorization holder

Eli Lilly (Suisse) SA

1214 Vernier

Authorization information

Swissmedic authorization number
69523
Drug name
Kisunla, Konzentrat zur Herstellung einer Infusionslösung
Galenic form
KOINF
ATC Code
N06DX05
Authorization status
Z
Dispensation category
A
First authorization
22/01/2026
Authorization expiration date
21/01/2031
IT number
01.99.0.
Domain
Human medicine

Packaging details

Description (FR)
KISUNLA conc perf 350 mg 1 pce
Description (DE)
KISUNLA Konz Inf 350 mg 1 Stk
Market launch
25/02/2026
Narcotic (BTM)
No
Buy us a coffee Explore the data